Business Description
Prime Medicine Inc
NAICS : 541714
SIC : 2833
ISIN : US74168J1016
Description
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.81 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -455 | |||||
| 3-Year EPS without NRI Growth Rate | -133.3 | |||||
| 3-Year FCF Growth Rate | -181.3 | |||||
| 3-Year Book Growth Rate | 246 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.34 | |||||
| 9-Day RSI | 73.7 | |||||
| 14-Day RSI | 64.77 | |||||
| 6-1 Month Momentum % | -18.95 | |||||
| 12-1 Month Momentum % | -54.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.91 | |||||
| Quick Ratio | 8.91 | |||||
| Cash Ratio | 8.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 | |||||
| Shareholder Yield % | -16.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -33773.27 | |||||
| Net Margin % | -34601.86 | |||||
| FCF Margin % | -33943.65 | |||||
| ROE % | -93.83 | |||||
| ROA % | -76.18 | |||||
| ROIC % | -246.16 | |||||
| ROC (Joel Greenblatt) % | -398.05 | |||||
| ROCE % | -85.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1079.65 | |||||
| PB Ratio | 3.31 | |||||
| Price-to-Tangible-Book | 3.31 | |||||
| EV-to-EBIT | -3.15 | |||||
| EV-to-EBITDA | -3.23 | |||||
| EV-to-Revenue | 1064.08 | |||||
| EV-to-FCF | -3.01 | |||||
| Price-to-Net-Current-Asset-Value | 5.38 | |||||
| Price-to-Net-Cash | 5.65 | |||||
| Earnings Yield (Greenblatt) % | -31.75 | |||||
| FCF Yield % | -24.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRME
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prime Medicine Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.591 | ||
| EPS (TTM) ($) | -2.18 | ||
| Beta | 0 | ||
| Volatility % | 77.85 | ||
| 14-Day RSI | 64.77 | ||
| 14-Day ATR ($) | 0.539157 | ||
| 20-Day SMA ($) | 5.20125 | ||
| 12-1 Month Momentum % | -54.95 | ||
| 52-Week Range ($) | 4.11 - 17.2 | ||
| Shares Outstanding (Mil) | 120.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prime Medicine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prime Medicine Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Prime Medicine Inc Frequently Asked Questions
What is Prime Medicine Inc(PRME)'s stock price today?
The current price of PRME is $6.72. The 52 week high of PRME is $17.20 and 52 week low is $4.11.
When is next earnings date of Prime Medicine Inc(PRME)?
The next earnings date of Prime Medicine Inc(PRME) is 2024-08-07 Est..
Does Prime Medicine Inc(PRME) pay dividends? If so, how much?
Prime Medicine Inc(PRME) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers